Clinuvel Is Planning For US Commercialization Of Ultra-Orphan Drug Scenesse

Clinuvel's Scenesse for the ultra-rare, light-induced disease erythoropoietic protoporphyria (EPP) is already approved in Europe and the company is hopeful that a rolling NDA submission could pave the way for a US launch.

Early morning sky background, sunlight through white clouds and free birds flying away

Clinuvel Pharmaceuticals Ltd. launched Scenesse (afamelanotide) in Europe in 2016 and now the company is preparing a similar commercialization and pricing strategy for the ultra-orphan drug in the US. The company has submitted a rolling NDA to the FDA for Scenesse for patients with erythropoietic protoporphyria (EPP), an ultra-rare condition that causes severe reactions to light, or phototoxicity.

The company, based in Melbourne Australia, announced the rolling new drug application (NDA) submission in June, but on Sept. 5...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip